Tumor-related gene mutation analysis is a critical method utilized by pharmaceutical companies during the development of oncology drugs for patient stratification and enrollment, resistance mechanism research, and biomarker discovery. Relying on multi-omics technological capabilities, Sequanta has built a comprehensive genomic profiling platform covering various gene panel sizes, tumor types, ard technological routes. This platform provides pharmaceutical companies with full-process molecular testing solutions from early R&D to post-market monitoring. The platform deeply empowers clinical trials for solid and hematological tumors, fully complies with different domestic and international regulatory requirements, and accelerates the highlyefficient research and rapid market launch of tumor-targeted drugs and ICBs (Immune Checkpoint Inhibitors).
